Skip to main content
OpenTrials
Completed

NCT Number: NCT03314051

Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasopharyngeal Carcinoma Carcinoma EBV Related Carcinoma Head and Neck Neoplasms Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Stomatognathic Diseases

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

About this study

The stage III NPC patients were the majority group of the patient population of NPC. But most clinical trials focused on the treatment of American Joint Committee on Cancer (AJCC) 7th edition stage IVA/IVB treatment for high risk of recurrence or metastasis. No previous study reported the treatment outcome of stage III NPC patients. The investigators tried to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biopsy-proven stage III nasopharyngeal carcinoma (NPC)
  • Finished curative chemoradiotherapy
  • Have Pre-treatment and post-radiotherapy plasma EBV DNA

Exclusion criteria

  • No tissue proven NPC
  • Not finished curative treatment
  • No Pre-treatment and post- radiotherapy plasma EBV DNA

Treatment and study plan

Primary outcomes

  1. Overall survival (OS)

    Time frame: 5 year

    Diagnosis to death

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: 5 year

    Diagnosis to death to recurrence or metastasis

  2. Distant metastasis failure-free survival (DMFFS)

    Time frame: 5 year

    Diagnosis to death to distant metastasis

  3. Locoregional failure-free survival (LRFFS)

    Time frame: 5 year

    Diagnosis to death to locoregional failure

Sponsors and collaborators

Lead sponsor

Taichung Veterans General Hospital

Other

Registry information

Official study title

Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA

Important dates

Study start
2012
Primary completion
2013
Study completion
2016
First posted
Oct 19, 2017
Registry last updated
Oct 20, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.